Pfizer, COVID-19 and vaccine
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...
We recently compiled a list of the 8 Best Wide Moat Stocks to Buy According to Analysts. In this article, we are going to ...
Pfizer's stock underperformed its healthcare peers since PFE topped out in late July 2024. Click here to find out why I ...
Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...
This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical ...
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $35.00. The ...
In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...
Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.5 which represents a slight increase of $0.19 or 0.65% from the prior close of $29.31. The stock opened at $29.25 and touched a low of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback